-
Ozempic, Wegovy, Other GLP-1 Semaglutide Weight-Loss Drugs Linked to Gastroparesis in Recent Medical Study
Researchers Compared Semaglutide Drugs, Such as Ozempic and Wegovy, to Contrave, a Non-GLP-1 Drug, in Weight-Loss Patients (Posted by Tom Lamb at Drug Injury Watch) An October 2023 medical journal article presented the results of…
-
Apellis Updates Number of Syfovre Retinal Vasculitis Cases But Provides No Further “Explanation”
On That Aspect, in August 2023 Apellis Asked Doctors to Stop Using Syfovre Injection Kits With a 19-gauge Filter Needle (Posted by Tom Lamb at Drug Injury Watch) UPDATE: From this February 28, 2024, Fierce Pharma…
-
Ozempic: Reports of Gastrointestinal Disorder Ileus Added to Drug Label in September 2023
Paralytic Ileus, the Slowing of Food Movement Through Digestive System, is Similar to Intestinal Obstruction (Posted by Tom Lamb at Drug Injury Watch) In September 2023 the Ozempic (semaglutide) drug label was updated to inform…
-
Severe Stomach Conditions in Patients Using Semaglutide Weight Loss Drugs From Novo Nordisk
Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis (Posted by Tom Lamb at Drug Injury Watch) Semaglutide is the active ingredient in three Novo Nordisk drugs that are being used…
-
Syfovre Adverse Reaction Cases: Updated Number of Patients With Retinal Vasculitis, Timeline of Events
Additional Information from Apellis and the American Society of Retina Specialists About Ongoing Syfovre Safety Issues (Posted by Tom Lamb at Drug Injury Watch) UPDATE: From this February 28, 2024, Fierce Pharma news report, "Apellis cites…